Managing CMR

Preventing Type 2 Diabetes

Targeting Abdominal Obesity

Pharmacotherapy for the Prevention of Type 2 Diabetes

Page: Go to Previous Page 11 of 12 Go to Next Page

In summary, pharmacological compounds designed to mobilize atherogenic intra-abdominal fat need to be developed in order to improve the diabetic dyslipidemia and disruption of plasma glucose-insulin homeostasis caused by excess intra-abdominal fat.

Given that abdominal obesity is one of the most prevalent forms of type 2 diabetes, therapeutic approaches should focus on reducing intra-abdominal adipose tissue. This should have an impact on the causal pathways leading to insulin resistance, impaired glucose tolerance, and type 2 diabetes. Very few pharmacological compounds target intra-abdominal adipose tissue directly. Health professionals should focus first on reshaping patient lifestyles through increased physical activity and better eating habits. These measures have proven effective in reducing intra-abdominal fat and should be promoted to the general population as valid ways to prevent obesity-related health problems.